Tocilizumab in severe and refractory non-infectious uveitis

, , , , , , , , ,

Service de Médecine Interne, Hôpital Pitié-Salpêtrière 47-83 boulevard de l'Hôpital 75013 Paris, France. matt.papo@gmail.com

CER7235 Submission on line
2014 Vol.32, N°4 ,Suppl.84 - PI 0075, PF 0079
Full Papers

Free to view (click on article PDF icon to read the article)

Rheumatology Article



To report the safety and efficacy of tocilizumab in patients with severe and refractory non-infectious uveitis.
Eight consecutive unselected patients with severe and refractory non-infectious uveitis [Birdshot chorioretinopathy (n=1), Behçet`s disease (n=1) and idiopathic bilateral panuveitis (n=6)] treated with tocilizumab (8mg/kg every 4 weeks intravenously) were included. The primary outcome was the response to treatment, defined by decrease of inflammatory ocular signs.
Four (50%) patients were of female gender and the median (IQR) age was 41 (31-47) years. The median number of previous immunosupressants was of 5.5 (4–6.7). Seven patients had been previously treated with anti-TNF-α [infliximab (n=5) and adalimumab (n=2)]. The immunosupressive drugs used in association with tocilizumab were azathioprine (n=2), mycophenolate mofetil (n=2) and methotrexate (n=2). After a median follow-up of 8 months (6–25), 6/8 (75%) improved under tocilizumab and 2 (25%) were non-responders. The visual acuity improved in five patients. The median dose of prednisolone decreased from 16mg/day (10.6–20.5) to 10 mg/day (10–13.7), at baseline and at the end of follow-up, respectively. Tolerance of tocilizumab was satisfactory and side effects included bronchitis (n=1) and grade 1 leukopenia (n=1) and thrombocytopenia (n=1).
Tocilizumab seems to be a safe and promising therapy in severe and refractory non-infectious uveitis.

PMID: 25268663 [PubMed]

Received: 06/01/2014 - Accepted : 15/05/2014 - In Press: 30/09/2014 - Published: 30/09/2014